GOLDMAN SACHS
Pilbara Minerals Ltd. (PLS.AX): 3QFY24 in line; Net cash of ~A$1.4bn leaves FY24 div unlikely; Offtakes may limit spod price upside; Sell
19 April 2024 | 7:41PM AEST
PLS reported in line spodumene production of 179kt, with shipments of 165kt up 3% QoQ, but below GSe/consensus on timing of shipments. Unit costs of A$675/t (FOB; pre-royalties) were broadly in line with market expectations, and growth projects remain on track.
Realised pricing of US$804/t (US$927/t SC6.0 CIF China) was down ~30% QoQ, though broadly in line with market expectations. While provisional pricing modestly impacted Dec-23 quarter sales prices, a cash final pricing adjustment of -A$218mn impacted cash flow in the quarter.
However, PLS’ capture of improvements in spodumene prices is likely limited given the large portion of near-term volumes committed to offtake agreements (~90%+ over FY24-25E, also limiting auction capacity). Due to a significant portion of volume being linked to chemicals pricing (broadly remained flat since the beginning of March), despite the recent improvement in spodumene prices following a small number of auctions, we see this limiting any potential uplift of PLS’ realised spodumene prices into the Jun-24 quarter.
Furthermore, this greater contracted exposure may also slow the realisation of any broader lithium complex price rises/falls for PLS vs. peers. PLS’ net cash declined to A$1.4bn (from ~A$1.8bn) and has almost halved over the last 6 months (partly on catch up FY23 tax in the Dec-23 quarter). As a result, we see a FY24 final dividend as increasingly unlikely (prior GSe ~A2cps) given capital spend, realised lithium pricing challenges, and PLS having already deferred non-essential spend/the 1H dividend to preserve a balance sheet advantage (though expect dividends to return with the FY25 interim result).
We note that on our numbers, both before/after including a Beyond P1000 expansion, net cash troughs at ~A$0.8-0.9bn (before likely longer dated downstream capex).
Our 12m PT is down to A$2.80/sh, where PLS (Sell) remains at a premium to peers (1.2x NAV & pricing ~US$1,300/t LT spodumene (including a nominal value of A$1.1bn for growth); peer average ~1.05x & ~US$1,210/t (lithium pure-plays ~US$1,110/t; GSe US$1,150/t LT real)), with near-term FCF continuing to decline on lithium prices and increasing growth spend (c.-10% FCF yield in FY24E, and c.0% in FY25-27E).
We also continue to see risk that a Beyond P1000 expansion disappoints vs. market expectations on a combination of capex, size, or timing
- Forums
- ASX - General
- EV/Lithium
GOLDMAN SACHS Pilbara Minerals Ltd. (PLS.AX): 3QFY24 in line;...
- There are more pages in this discussion • 255 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
SPONSORED BY The Market Online